Roche, Biogen end dispute. 70 confirmed cases of PML. Print E-mail
By Mary Davila   
Thursday, 21 October 2010 19:10

Below is a look at some of the headlines for companies that made news in the healthcare sector on October 21, 2010.

Roche, Biogen end dispute - Biogen Idec Inc (NASDAQ:BIIB) and Roche Holding AG's (OTC:RHHBY) Genentech unit agreed to amend the terms of their collaboration over Rituxan follow-ons to develop antibody drugs, ending a long-term dispute.

Genentech will be responsible for further development and commercialization of ocrelizumab in multiple sclerosis. Biogen will receive tiered, double-digit royalties, close to its 30 percent interest, on future U.S. sales of the experimental drug that will be in the compound.

The new terms do not affect their profit split for Rituxan, the big-selling drug used to treat non-Hodgkin's lymphoma (NHL) and rheumatoid arthritis.

Biogen reports more brain infections in MS patients - Two more patients taking Tysabri have developed a potentially deadly brain infection known as PML, Biogen Idec Inc's multiple sclerosis drug.

Biogen  (NASDAQ:BIIB) said in its latest monthly update that as of October 1, there have been 70 confirmed cases of PML, up from 68 as of September 2, 14 of those have died and 56 are alive with varying degrees of disability ranging from mild to severe. There were no additional deaths in October.

Tysabri, which Biogen sells in partnership with Irish drugmaker Elan Corp Plc (NYSE:ELN), is an important growth driver for both companies, and is battling for share of an increasingly competitive market.

U.S. regulators recently approved the first oral MS drug, Gilenya, made by Novartis AG (NYSE:NVS), which, while not as effective as Tysabri, is more convenient, since Tysabri must be infused roughly once a month.

Here are other companies that made news on Thursday:


Auxilium Pharmaceuticals, Inc. (Nasdaq:AUXL), a specialty biopharmaceutical company, will release results for the third quarter 2010 on Thursday, November 4, 2010 before the opening of the financial markets.

BIOLASE Technology, Inc. (NASDAQ: BLTI)
, the world's leading dental laser company, announced today that the Company will host a conference call on Tuesday, November 2, at 11:00 a.m. Eastern Time to discuss its operating results for the third quarter and nine months ended September 30, 2010, and to answer questions.

Caliper Life Sciences, Inc. (Nasdaq:CALP) today announced the availability of a new, higher sensitivity DNA assay for its LabChip GX analytical platform, as well as the new Sciclone NGS Workstation.

Cord Blood America, Inc. (OTC Bulletin Board:CBAI), the umbilical cord blood stem cell preservation company focused on bringing the life-saving potential of stem cells to families nationwide and internationally, is pleased to announce that Chairman, CEO and co-founder Matthew Schissler and Dr. Geoffrey O'Neill, Vice President, Operations, will appear for one hour live on "Go Rogue & Get Rich" on The VoiceAmerica Radio Network.

GeckoSystems Intl. Corp. (PINKSHEETS:GCKO) announced today that they have received an update regarding their formal request to the Financial Industry Regulatory Authority (FINRA) to change their trading symbol to one more representative of their company's strategic focus and operations.

Genoptix, Inc. (Nasdaq: GXDX), a specialized laboratory services provider, announced today that it expects to report its financial results for the third quarter 2010 after closing of the NASDAQ Global Select Market on Thursday, November 4, 2010.

InoLife Technologies, Inc. (OTCBB: INOL), a service based healthcare products development, integration and marketing Company announced today the launch and marketing of its Ancestry DNA test for immediate availability to the consumer market.

Medtronic, Inc. (NYSE:MDT) announced today the Canadian launch of a novel technology designed to provide additional protection against the risks associated with hypoglycemia.

OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) announced today that the Company's third quarter financial results will be released on Thursday, November 4, 2010, and that the Company will host a conference call and live webcast at 4:30 p.m. ET that afternoon.

Protectus Medical Devices, Inc. (OTCQB: PTMD) (PINKSHEETS: PTMD), a developer and marketer of innovative safety medical devices, announces that the Company's prior filed application for patent protection in the country of Taiwan, which corresponds to the recently grantedU.S. Patent No. 7,799,002 ("Safety Syringe"), has now been documented in the Official Gazette of the Taiwan Patent Office and is undergoing substantive examination.

Transdel Pharmaceuticals, Inc. (OTC Bulletin Board:TDLP), a specialty pharmaceutical company focused on developing topically administered products using its proprietary transdermal delivery platform, today announced the appointment of John N. Bonfiglio, Ph.D. as Chief Executive Officer and President.

United Therapeutics Corporation (Nasdaq:UTHR) announced today that it will release its third quarter 2010 financial results before market open on Thursday, October 28, 2010.

VIVUS, Inc. (Nasdaq:VVUS) today announced that data on QNEXA®, an investigational drug candidate, will be featured in two oral presentations at the 1st International Diabetes and Obesity Forum, being held October 21-23, 2010 in Athens, Greece.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus